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Abstract Mouse models of type I diabetes offer the potential
to combine genetic approaches with other pharmacological or
physiological manipulations to investigate the pathophysiol-
ogy and treatment of diabetic retinopathy. Type I diabetes is
induced in mice through chemical toxins or can arise
spontaneously from genetic mutations. Both models are
associated with retinal vascular and neuronal changes. Retinal
transcriptomic responses in C57BL/6J mice treated with
streptozotocin and Ins2
Akita/+ were compared after 3 months
of hyperglycemia. Specific gene expression changes suggest
a neurovascular inflammatory response in diabetic retinopa-
thy. Genes common to the two models may represent the
response of the retina to hyperglycemia, while changes
unique to each model may represent time-dependent disease
progression differences in the various models. Further
investigation of the commonalities and differences between
mouse models of type I diabetes may define cause and effect
events in early diabetic retinopathy disease progression.
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Introduction
A variety of rodent models of type I diabetes are used for
preclinical investigation of diabetic retinopathy. These models
vary according to species (rat or mouse), strain, method of
diabetes induction,andduration of diabetes [1]. Depending on
the aims of a particular study, a strong rationale exists for any
number of combinations of these factors. However, this
multiplicity of models complicates comparisons between
reports and makes difficult the interpretation of fundamental
mechanisms underlying the development of diabetic retinop-
athy. To assess similarities in the most basic molecular
changes, studies have been conducted across species and
strains to identify commonalities and differences in retinal
gene and protein expression [2, 3].
As part of efforts in preclinical drug development for
diabetic retinopathy, we have previously utilized the
streptozotocin-treated (STZ) Sprague–Dawley rat model
[4–7]. However, mouse models of type I diabetes, permit-
ting ease of genetic manipulation, offer an advantage in
disease and therapeutic studies of diabetic retinopathy.
STZ-induced diabetic mice have hallmark aspects of
retinopathy such as neuronal cell death and vascular
dysfunction [8–10]. Recent efforts, lead by the National
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DOI 10.1007/s12177-009-9045-3Institutes of Health-sponsored Animal Models of Diabetic
Complications Consortium, have standardized the STZ
induction protocol (http://www.amdcc.org). However, the
availability of Ins2
Akita, a spontaneous, early onset genetic
model of type I diabetes with complete penetrance, avoids
the effects of STZ on non-insulin producing cell types and
provides an attractive alternative.
We have described retinal complications in the Ins2
Akita
model of type I diabetes [11]. Akita designates a point
mutation in the Ins2 gene which leads to accumulation of
misfolded Ins2 protein in pancreatic beta cells and ultimately
beta cell death [12, 13]. Ins2
Akita mice are not obese and are
typically hyperglycemic by 5 weeks of age. In contrast to
other spontaneous models of type I diabetes in the mouse,
Ins2
Akita lacks intrinsic immune defects, allowing the retinal
inflammatory response to be examined solely in relationship
to diabetes-induced metabolic alterations; and it is dominantly
inherited on an inbred genetic background, greatly facilitating
studies that implement intercrosses with genetically altered
mice carrying various mutations that will permit testing of
new hypotheses and identification of new drug targets. We
have characterized the retinal complications in the Ins2
Akita
model of type I diabetes and have found increased vascular
permeability, leukostasis, and apoptosis, as well as retinal
morphological changes [11, 14, 15].
To compare two mouse models of type I diabetes, i.e.,
STZ-induced and Ins2
Akita, a gene expression analysis
was conducted examining whole retinas collected after
3 months of hyperglycemia. This time point was chosen as
it is the same duration as our previous work with the
Sprague–Dawley rat model of type I diabetes [4, 6]. Also,
we have demonstrated increased retinal vascular perme-
ability and apoptosis, and decreased ganglion cell density
and insulin receptor kinase activity at this time point in the
Ins2
Akita model [11]. Additionally, decreased ganglion cell
density and increased apoptosis are observed at this time
p o i n ta sw e l li nt h eI n s 2
Akita model [14]. The results from
the present study reveal common aspects of the retinal
response to diabetes across mouse (and rat) models with a
number of changes also specific to each model. Differ-
ences between the models prompting further examination
of the time course of retinal dysfunction in these model
systems.
Methods
Animal models of type I diabetes
All mice were maintained by the Penn State Diabetic
Retinopathy Animal Models Core in accordance with the
Institutional Animal Care and Use Committee guidelines
under specific pathogen-free conditions and monitored
by quarterly sentinel testing. Stock C57BL/6J mice (The
Jackson Laboratory, Bar Harbor, ME, USA) are replen-
ished twice a year and bred only one generation in
house.
C57BL/6J-Ins2
Akita/+ mice (The Jackson Laboratory, Bar
Harbor, ME, USA) were imported into the colony several
years ago and are continuously maintained by crossing with
C57BL/6J stock at each generation. Due to the asynchro-
nous replication and resulting inconsistency of the diabetes
in Ins2
Akita/+ female mice, only male mice were used for
these experiments. Ins2
Akita/+ males were phenotyped by
blood glucose at 5 weeks of age, and assignment was
verified by molecular genotyping of ear biopsies taken at
the time of retinal harvest (18 weeks).
Diabetes was induced according to the protocol from
the Animal Models of Diabetic Complications Consor-
tium http://www.amdcc.org/.B r i e f l y ,a t4 –5 weeks of age,
each day for five consecutive days, male C57BL/6J mice
were fasted for approximately 4 h prior to a single
intraperitoneal injection of 50 mg/kg streptozotocin
(Sigma-Aldrich, St. Louis, MO, USA) in 100 mM sodium
citrate buffer, pH 4.5. Blood glucose concentrations were
measured after 1 week and each subsequent week. Only
mice that had blood glucose concentrations of >250 mg/
dL by the end of the second week were included. Control
mice were injected with an equal dose of citrate buffer
only. STZ and control mice were harvested 12 weeks post-
STZ or buffer injection, thus approximately 18 weeks of
age. Mice had free access to food and water and were on a
12-h light/dark cycle. No exogenous insulin was deliv-
ered. Blood glucose concentrations and percent glycosy-
lated hemoglobin were measured from drops of blood
acquired by nicking the tail, using a Lifescan glucose
meter and Siemens DCA Analyzer, respectively. Car-
tridges for the quantitative measurement of hemoglobin
A1c are based on specific monoclonal antibody aggluti-
nation. At the time of retinal harvest, mice were given a
lethal dose of pentobarbital, 100 mg/kg (Ovation Pharma-
ceuticals Inc., Deerfield, IL, USA) by intraperitoneal
injection. Retinas were excised and quickly frozen in
liquid nitrogen and stored at −80°C prior to RNA isolation
using a protocol to produce standardized whole retinal
tissues [6, 11].
RNA isolation
Whole retina tissue was homogenized using a Retsch
TissueLyzer II (Qiagen, Valencia, CA, USA) with a 3-mm
stainless steel ball in 500 μL TriReagent (Molecular
Research Center, Cincinnati, OH, USA) for 30 s at 30 Hz.
After homogenization, RNA was isolated following stan-
dard Tri Reagent/BCP disruption and phase separation and
overnight isopropanol precipitation at −20°C. RNA was
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RNA was assessed for quantity and quality using a
NanoDrop ND1000 (Thermo Scientific, Wilmington, DE,
USA) and RNA 6000 Nano LabChip with an Agilent 2100
Expert Bioanalyzer (Agilent, Palo Alto, CA, USA),
respectively. All RNA used had RNA integrity values
greater than 8.
Illumina microarray analysis of mRNA expression
Microarray analysis was performed using Illumina Ref8
microarrays. For the Ins2
Akita experiment, n=8 wild-type
samples, and n=9 Ins2
Akita samples were analyzed. For the
STZ experiment, n=8 control and n=6 STZ-treated animals
were analyzed. Samples were labeled according to Illumina
TotalPrep RNA Amplification kit (Illumina, San Diego,
CA, USA) standard procedures. RNA (250 ng) was reverse
transcribed to synthesize first strand cDNA by incubating
samples at 42°C for 2 h with T7 Oligo(dT) primer, 10×
First Strand buffer, dNTPs, Rnase inhibitor, and Array-
Script. Second strand cDNA was synthesized with 10×
second strand buffer, dNTPs, DNA polymerase and Rnase
H at 16°C for 2 h. cDNAwas purified according to standard
procedures. cDNA was eluted in approximately 17.5 μL
55°C nuclease-free water and stored at −20°C overnight.
cDNA was in vitro transcribed to synthesize cRNA using
MEGAscript (Ambion) kit. Samples were incubated with
T7 10× Reaction buffer, T7 Enzyme mix and Biotin-NTP
mix at 37°C for 14 h. cRNA was purified according to
instructions. cRNA yield was measured using a NanoDrop
ND1000 (Thermo Scientific, Wilmington, DE, USA).
Purified cRNA (750 ng) was prepared for hybridization
according to instructions for hybridizing to Illumina
MouseRef-8 Expression BeadChips. BeadChips were incu-
bated in a hybridization oven for 20 h at 58°C at a rocker
speed of 5. After 20 h, BeadChips were disassembled and
washed and Streptavadin-Cy3 stained according to Illumina
standard procedures. BeadChips were dried by centrifuga-
tion at 275×g for 4 min and subsequently scanned using a
BeadArray Reader.
BeadStudio (Illumina) flat files were imported into
GeneSpring 7.3 (Agilent) software for data analysis. Each
experiment (STZ and Ins2
Akita) was treated separately for
statistical analyses. Initially probes were filtered to remove
those for which no transcript was detected. Using the
detection p values initially generated in BeadStudio, probes
were required to have detectable signal for six of 14 arrays
in the STZ experiment and eight of 17 arrays for the
Ins2
Akita to be included in the subsequent statistical
analyses. The goal of this filtering is to eliminate transcripts
not reliably detected from further analysis, while retaining
genes potentially expressed in only one group (i.e.,
expressed only in control or only in diabetic). Therefore,
the thresholds were chosen based on the smallest number of
samples in a group. The full complement of microarray data
is available in the Gene Expression Omnibus [16],
accession # GSE19122.
To determine differential expression, a combination of
statistical p value (t test, p<0.05) and fold-change (≥1.4
fold) cutoffs were used in accordance with standards in data
analysis [17] and our previously published methods [6].
Quantitative RT-PCR
Quantitative polymerase chain reaction (qPCR) analysis
was performed as described previously [4, 6] using the
7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA, USA), 384-well optical plates, and Assay-
On-Demand (Applied Biosystems) gene specific primers
and probes. SDS 2.2.2 software and the 2ΔΔCt analysis
method were used to quantitate relative amounts of product
using β-actin as an endogenous control. β-actin levels were
determined to be unchanged in an absolute quantification
experiment (data not shown). For a full listing of primer/
probe sets, see Table 1.
Results
Assessment of diabetes
Mice were harvested after 3 months of hyperglycemia.
For the STZ-treated mice, this was 3 months after the
last STZ injection. Ins2
Akita mice were harvested at
4 months of age. At sample collection, both STZ-induced
and Ins2
Akita-diabetic mice had significantly elevated blood
glucose as compared to the controls (p<0.001, t test), see
Table 2. Hyperglycemic mice were significantly lighter than
their respective controls (p<0.001), but no differences in
weight were evident between Ins2
Akita and STZ-treated
groups, see Table 2.
While glycosylated hemoglobin (HbA1c) percentages
were not measured in the mice harvested for the gene
expression experiments, HbA1c percentages were measured
in independent sets of animals after the same duration of
diabetes (Table 3). HbA1c percentages do not differ
between STZ-induced diabetic mice and Ins2
Akita diabetic
mice.
Microarray profiling of gene expression
Expression profiling of whole retina RNA from both the
STZ and Ins2
Akita experiments was performed after
3 months of hyperglycemia. Initial filtering for only those
probes with detectable signal revealed 16,327 probes
detected in six or greater of 14 microarrays in the STZ
204 j ocul biol dis inform (2009) 2:202–213experiment and 16,165 probes detected in eight or greater
of 17 microarrays in the Ins2
Akita experiment (Fig. 1a). Of
the detected probes, 15,818 (95%) were detected in
common between the two experiments.
In the STZ experiment, 333 probes, corresponding to
307 genes, were differentially expressed (p<0.05 and
>1.4-fold) in diabetic mice as compared to control mice
(Fig. 1b and Supplementary File 1). In the Ins2
Akita
experiment, 404 probes corresponding to 392 genes were
differentially expressed (p<0.05 and >1.4-fold) in diabetic
mice as compared to control mice. When examined, the
differentially expressed transcripts in the two experiments
were evenly distributed between upregulated and down-
regulated transcripts in the diabetic mice as compared to
Table 1 Gene symbols, names, alias, assay-on-demand catalogue numbers, and gene IDs for genes examined by quantitative polymerase
chain reaction
Symbol Name AOD Gene ID number Abbreviations/alias
B2M Beta-2 microglobulin Mm00437762_m1 Mm.163 Ly-m11
C1-Inh Serine (or cysteine) peptidase inhibitor,
clade G, member 1
Mm00437834_m1 Mm.38888 Serping1
C1S Complement component 1, s subcomponent Mm00663210_mH Mm.219527 C1sa
Carhsp1 Calcium regulated heat stable protein 1 Mm00787963_s1 Mm.142095 Crhsp-24
Ccr5 Chemokine (C-C motif) receptor 5 Mm01216171_m1 Mm.14302 Cmkbr5
Ch25h Cholesterol 25-hydroxylase Mm00515486_s1 Mm.30824 m25OH
Chi3L1 Chitinase 3-like 1 Mm00801477_m1 Mm.38274 Brp39
Csrp3 Cysteine and glycine-rich protein 3 Mm00443379_m1 Mm.17235 CRP3, MLP, MMLP
Dcamkl1 Doublecortin-like kinase 1 Mm00444950_m1 Mm.393242 Dclk
Edn2 Endothelin 2 Mm00432983_m1 Mm.284855 VIC
Ednrb Endothelin receptor type B Mm00432989_m1 Mm.229532 ETR-b
Egr1 Early growth response 1 Mm00656724_m1 Mm.181959 Zenk, Zfp-6, Zif268
Fmod Fibromodulin Mm00491215_m1 Mm.287146 SLRR2E
Gbp2 Guanylate binding protein 2 Mm00494575_m1 Mm.24038
Gldc Glycine decarboxylase Mm00506891_m1 Mm.274852
H2-Ab1 Histocompatibility 2, class II antigen A, beta 1 Mm00439216_m1 Mm.254067 I-Abeta, IAb, Ia-2, Ia2, Rmcs1
Hspb1 Heat shock protein 1 Mm00834384_g1 Mm.13849 Hsp25
Icam1 Intercellular adhesion molecule 1 Mm00516023_m1 Mm.435508 MALA-2
IFitm3 Interferon-induced transmembrane protein 3 Mm00847057_s1 Mm.141021 Cd225, Cdw217, Fgls, IP15,
mil-1
Jak3 Janus kinase 3 Mm00439962_m1 Mm.249645 Fae, wil
Kcne2 Potassium voltage-gated channel,
Isk-related subfamily, gene 2
Mm00506492_m1 Mm.156736 MiRP1
Lama5 Laminin, alpha 5 Mm01222050_g1 Mm.4339 Laminin-511
Lgals3 Lectin, galactose binding, soluble 3 Mm00802901_m1 Mm.248615 GBP, L-34, Mac-2, gal3
Lgals3bp Lectin, galactoside-binding, soluble,
3 binding protein
Mm00478303_m1 Mm.3152 CyCAP, MAC-2BP, Ppicap
Lgals9 Lectin, galactose binding, soluble 9 Mm00495295_m1 Mm.341434 Gal-9, galectin-9
Mct1 Solute carrier family 16 (monocarboxylic acid
transporters), member 1
Mm00436566_m1 Mm.9086 Slc16a1
Nppa Natriuretic peptide precursor type A Mm01255747_g1 Mm.19961 ANP, Anf, Pnd
Pcgf1 Polycomb group ring finger 1 Mm01617932_g1 Mm.12261 Nspc1
Pedf Serine (or cysteine) peptidase inhibitor, clade F,
member 1
Mm00441270_m1 Mm.2044 Serpinf1
Slc6a11 (Gat3) Solute carrier family 6 (neurotransmitter
transporter, GABA), member 11
Mm00556476_m1 Mm.44683 Gat3, GAT4, Gabt4
Stat3 Signal transducer and activator of transcription 3 Mm00456961_m1 Mm.249934 Aprf
Timp1 Tissue inhibitor of metalloproteinase 1 Mm00441818_m1 Mm.8245 Clgi, Timp
Tnfrsf12a Tumor necrosis factor receptor superfamily,
member 12a
Mm00489103_m1 Mm.28518 Fn14, HPIP, TWEAK-R
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variance was observed within groups of diabetic and
control mice, but clearly altered levels in expression were
observed between control and diabetic animals. In both
experiments, 30 probes corresponding to 28 genes were
differentially expressed in Ins2
Akita and STZ mice (Fig. 1b
and Table 4). For all of these commonly regulated
transcripts between the two mouse models of type I
diabetes, transcripts were either upregulated or downregu-
lated in both models, and none were regulated in opposing
directions.
The lists of differentially expressed genes in the two
experiments were imported into the Ingenuity Pathway
Analysis software for analysis of patterns of gene
expression. Network analysis was performed on the
results of the two experiments. Network analysis is
intended to statistically identify sets of interrelated genes
based on their known functions. For the Ins2
Akita
experiment, the most significantly regulated network of
genes related to inflammatory processes (Fig. 2a). For the
STZ experiment, the most significantly regulated network
centered on genes with known responsiveness to diabetes
in either clinical samples or animal models (Fig. 2b).
While the two experiments highlighted two different
networks, both fit with a hypothesis of diabetic retinop-
athy as a feed-forward cycle of neuroinflammation [18].
To confirm differentially expressed transcripts in both
models of type I diabetes, focused qPCR validation of
microarray experiments was performed. Six genes (B2m;
cysteine and glycine-rich protein 3 (Csrp3); interferon-
i n d u c e dt r a n s m e m b r a n ep r o t e i n3( Ifitm3); Lgals9;H 2 A
histone family, member B3 (H2Ab1); and Ch25h)w e r e
chosen for confirmation, of which, four genes demonstrat-
ed a statistically significant altered level of expression in
both mouse models by qPCR (Fig. 3). These genes were
chosen for qPCR confirmation to confirm the validity of
the microarray measurements and due to their being some
of the largest magnitude changes. Increased expression of
B2m, Ifitm3,a n dLgals9 and reduced expression of Csrp3
was observed in the diabetic mice as compared to their
respective control mice. Significantly, increased H2Ab1
expression was observed only in the STZ-diabetic mice
relative to controls. Ch25h expression was not significantly
altered in the qPCR confirmation but did trend towards
upregulation, as observed in the microarray analysis.
Additionally, three transcripts (Egr1, fibromodulin
(Fmod), and glycine dehydrogenase (Gldc)) were exam-
ined by qPCR which were observed to be altered in only
one mouse model by the microarray analysis (Fig. 4).
Egr1 was downregulated in Ins2
Akita mice alone, while
Fmod and Gldc were upregulated in STZ mice alone in the
microarray analysis. qPCR validation confirmed decreased
expression of Egr1 in Ins2
Akita diabetic mice as compared
to controls, but no change was observed in the STZ-
diabetic mice as compared to their controls. Increased
expression of Fmod,a n dGldc was observed in STZ
diabetic mice relative to control mice in qPCR validation.
No change was observed in Ins2
Akita diabetic animals as
compared to controls in the qPCR measurements. In total,
eight of the nine genes examined by qPCR validated the
microarray results an indication of the reliability of the
microarray data generated.
Previously, we examined whole retina mRNA expres-
sion changes in the STZ-induced Sprague–Dawley rat
model of type I diabetes at 3 months of hyperglycemia
[6]. We also demonstrated that a set of retinal genes, a
biomarker panel, are accurate classifiers of disease state
and may be used to gauge the efficacy of therapies in
preclinical drug development using that model system [4].
This biomarker panel of 24 genes was also developed for
3 months of hyperglycemia time point. The genes in the
biomarker panel were also examined in the retinal mRNA
from the STZ and Ins2
Akita experiments by qPCR for
potential commonalities in gene expression changes
(Table 5). Some common changes were observed with
increased expression of C1Inh and decreased expression
of Kcne2 in STZ and Ins2
Akita diabetic mice as compared
to their respective controls. Additionally, Gbp2 and
Lgals3bp expression was evident in the STZ diabetic
mouse and increased laminin alpha 5 (Lama5) in the Ins2
Akita
diabetic mouse. While only a minority of the rat mRNA
biomarkers were observed to change in these mouse models,
it is of interest to note that all of those common changes
were of the same direction and magnitude.
Table 3 HbA1c percentages measured in an independent set of
animals at the same duration of hyperglycemia
Model n HbA1c (%)
Mean SD
C57BL/6J-Ins2
+/+ 19 4.6 0.3
C57BL/6J-Ins2
Akita/+ 9 12.1 1.2
C57BL/6J-Control 5 4.4 0.2
C57BL/6J-STZ 5 11.7 2.9
Table 2 Animal blood glucose and body weights
Model Blood glucose (mg/dL) Weight (g) n
Mean SD Mean SD
C57BL/6J-Ins2
+/+ 172 41 31.4 3.3 8
C57BL/6J-Ins2
Akita/+ 558 38 24.5 1.8 9
C57BL/6J-control 155 26 29.4 2.2 8
C57BL/6J-STZ 511 41 23.1 2.8 6
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Fig. 1 Microarray analysis of
retinal gene expression after
3 months of hyperglycemia. a
95% of the probes with detect-
able signal in the microarray
analysis were shared between the
two mouse models of type 1
diabetes. b Set analysis of the
sets of differentially expressed
(p<0.05, ≥1.4-fold) probes and
genes in the two models reveals
changes common to both models.
The majority of expression
changes were specific to one
model or the other. c Probes
with statistically significant dif-
ferences in signal (p<0.05) and
≥1.4-fold change are plotted for
each animal in the analysis. The
normalized (to a mean control
level of 1) intensity is plotted on
the y-axis with each individual
animal analyzed on the x-axis
for both experiments. Each
horizontal line is an individual
probe. This presentation provides
an overview of the interanimal
variance as well as differences
between the groups
j ocul biol dis inform (2009) 2:202–213 207Discussion
The present study examined diabetes-responsive retinal
gene expression to advance three related goals: (1) provide
targets for future biomarker development, (2) increase
knowledge of the retinopathological process in diabetes
though comparison of a toxin-induced and a spontaneous
genetic form of type I diabetes, and (3) compare the
similarity of retinal gene expression responses between
mouse and rat models of type I diabetes.
Biomarker development
As part of a translational diabetic retinopathy drug
development center, one of our goals is to develop and
optimize tools for enhancing the efficacy of preclinical drug
development. Previously, we have proposed a process for
the development and use of mRNA biomarkers in preclin-
ical drug development [4]. This biomarker discovery and
validation process was then used to create a diabetic
retinopathy mRNA biomarker panel for use with the STZ
rat model of type I diabetes [4]. The initial aspect of this
development process is biomarker target discovery, and one
of the goals of the present study was to conduct
biomarker target discovery in the STZ and Ins2
Akita mouse
models of type I diabetes. The expression changes
identified through microarray screening in the present study
can serve as biomarker targets for future validation and
classification analysis studies. The successful qPCR confir-
mation of targets from the microarray analysis suggests that
additional confirmations of microarray targets will be
successful.
Table 4 Common changes between the two models identified in the microarray discovery experiments
Probe number Mean ratio Ins2/WT Mean ratio STZ/control Gene symbol RefSeq ID
5910072 1.55 1.73 2310016A09RIK NM_181588.2
4830543 2.28 2.07 2310061N23RIK
7400603 1.45 1.55 2810004A10RIK NM_027265.1
1470647 0.66 0.65 9030221M09RIK NM_177298.2
4730458 2.60 2.27 ADAMTS19 NM_175506.2
2750209 1.58 1.80 AU040576 NM_178642.3
5570253 1.43 1.53 B2M NM_009735.2
3610025 1.93 1.97 BC004728 NM_174992.2
1510349 5.85 7.14 CH25H NM_009890.1
1450333 4.85 3.30 CLECSF12
3170255 4.93 3.58 CML4 NM_023455.2
1940154 1.66 1.94 COBLL1
5340722 0.70 0.70 CSRP3 NM_013808.3
2470133 0.64 0.61 CSRP3 NM_013808.3
4490730 1.54 1.69 D930038M13RIK NM_178790.2
4540382 1.51 1.62 EGFR NM_007912.4
1440307 1.66 1.90 H2-AB1 NM_207105.1
2570487 1.52 1.67 H2-AB1 NM_207105.1
840349 1.56 1.74 IFITM2 NM_030694.1
3840292 1.51 1.63 IFITM3 NM_025378.1
4880215 1.46 1.57 ITPR3 NM_080553.1
430132 1.97 2.01 LGALS9 NM_010708.1
1710768 1.97 2.04 LOC56628 NM_019909.1
2970598 1.47 1.61 MAP3K8 NM_007746.1
2490368 1.47 1.60 PLSCR2 NM_008880.2
6130743 1.43 1.46 ROR2 NM_013846.2
6840600 1.50 1.61 RRBP1 NM_133626.1
3830048 1.57 1.76 SELENBP1 NM_009150.2
380215 1.42 1.45 TOR3A
150424 0.55 0.55 XPO1 NM_001035226.1
Mean ratios are presented relative to control values for each of the two experiments
208 j ocul biol dis inform (2009) 2:202–213Effects of specific genes
A total of 13 genes were demonstrated by qPCR to be
differentially expressed with diabetes in this study. These
genes were selected to (1) confirm the validity of the
array measurements, (2) confirm genes identified in
common between the two models, and (3) examine
specific changes we have previously observed in the
STZ rat model. These confirmations are limited in
number, and additional targets from the microarray
analysis can be examined in future studies. Each of
these genes has potential actions in the pathophysiology
of diabetic retinopathy, and several has been previously
reported to be altered in expression in other animal
models of diabetes. A brief description of each of the
validated genes provides insight into how they may
contribute to the growing hypothesis of diabetic retinop-
athy as a feed forward cycle of inflammation, neuronal
damage, and microvascular dysfunction [18]. While
diabetic retinopathy research in the past has primarily
focused on vascular dysfunction, this hypothesis suggests
that neuronal, inflammatory, and vascular changes are
interrelated and that neuronal damage can induce inflam-
mation and vascular permeability.
Genes related to inflammatory process validated in
this study include C1-Inh, Gbp2, Ifitm3, and B2m. C1-
Inh (also known as serpin protease inhibitor, clade g
(Serping1)) has recently been described in a number of
clinical and animal model reports on diabetic retinopathy.
C1-Inh, induced in both the STZ and Ins2
Akita mouse
models, inhibits acute phase response signaling and the
classical complement systems through inhibition of C1r,
C1s, MASP-1, or MASP-2 [19]. Increased C1-Inh protein
expression has been observed in the vitreous of diabetic
patients [20, 21] as well as increased mRNA expression in
the retina of STZ-induced diabetic rats [4, 6, 22]. As an
inhibitor of complement activation, increased levels of
C 1 - I n hm a yb eac o m p e n s a t o r yr e a c t i o nt ol i m i tt h e
inflammatory response. In the retina, C1-Inh expression
has been localized to photoreceptors and inner nuclear
layer [23] .A st h er o l eo ft h ec o m p l e m e n ts y s t e mi nt h e
inflammatory aspects of diabetic retinopathy is becoming
better understood [24], this particular gene is an attractive
focus for further examination in mechanistic studies.
The role of Gbp2, induced in the STZ model (guanylate
binding protein 2, interferon-inducible) is poorly under-
stood in the retina, but Gbp2 has previously been
demonstrated to be induced in the retina of rat models of
type I diabetes [6, 22]. Gbp2 encodes a GTPase and is
induced in a number of extraretinal inflammatory
responses. Ifitm3, induced in both the STZ and Ins2
Akita
mouse models, is present in both neurons and endothelial
cells in brain [25] and has been previously reported to be
induced in the retina of diabetic rats [22]. Beta-2-
microglobulin (B2m), induced in both the STZ and
Ins2
Akita mouse models, is primarily known for its role in
antigen presentation but in type I diabetes is associated with
nephropathy and vascular complications [26]. B2m is
widely expressed in the retina [27] and induced levels of
B2m in the retina may play a similar role in vascular
dysfunction.
Several genes (Cspr3, Fmod, and Lama5) related to
tissue structure were observedt oi n c r e a s ei nt h ep r e s e n t
study. The function of Csrp3, reduced in expression in
both the STZ and Ins2
Akita mouse models, is unknown in
the retina, but the protein contains two LIM domains for
protein–protein interactions. The role of cysteine and
glycine-rich protein family genes in actin cytoskeleton
organization may be related to diabetes-induced alterations
in the retinal neuron morphology [14]. Fmod, induced in
only the STZ model, is a proteoglycan component of the
extracellular matrix. While the functional outcomes of
increased Fmod are unknown, its role in the extracellular
matrix may be of importance in diabetes-induced alter-
ations in retinal thickness [11] .L a m a 5 ,i n d u c e do n l yi nt h e
Ins2
Akita mice, is a member of the large laminin gene
family which are major components of basement mem-
branes. Specifically, Lama5 is present in the interphotor-
eceptor matrices and outer plexiform layer and associates
with the retinal vasculature [28]. Previous reports have
demonstrated diabetes-induced increases in other laminin
genes [29, 30], and we have observed increased Lama5
mRNA expression in the Sprague–Dawley, STZ-induced
diabetic rat after 3 months of diabetes [4].
Lgals3bp and Lgals9, increased in expression in both
models, are members of the galectin family of beta-
galactoside-binding proteins induced by a number of
inflammatory molecules and infections. While Lgals3bp
and Lgals9 are uncharacterized in the retina, they may
interact with Lgals3 in diabetes-induced blood-retinal-
barrier breakdown and accumulation of advanced glycation
end products [31]. Lgals3 null mice have been shown to
have less disruption of the blood-retina-barrier with
diabetes than wild-type mice [32].
Fig. 2 Network analysis of microarray data for each of the experi-
ments. Network analysis (ingenuity) identifies sets of genes with
known relationships that are unlikely (p<0.05) to occur by random
chance. The most significant network for each experiment is shown.
In the Ins2
Akita experiment, a network with a number of genes related
to inflammation (blue borders) was identified, while the STZ
experiment network contained a number of genes (blue borders) that
have been previously reported to be altered in mRNA or protein
expression in animal models or clinical specimens. Red indicates
upregulation, and green indicates downregulation of transcript levels.
Uncolored genes were not observed to be differentially expressed in
the microarray analysis but are integral parts of the network

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by qPCR (Egr1, Kcne2, Gldc, and H2Ab1) have less
clear relationships to the known pathophysiological
processes of diabetic retinopathy. The transcription factor
E g r 1 ,s u p p r e s s e di nt h eI n s 2
Akita mice, is best known for
its regulatory role in a large set of genes involved in
neuronal plasticity [33]. A potential role for increased
Egr1 expression has been suggested in retinal microglial
activation [34], but this role has yet to be fully elucidated,
and the functional outcome of the reduced Egr1 expres-
sion observed in the Ins2
Akita diabetic mouse remains to
be determined. The potassium voltage-gated channel, Isk-
related family, member 2 gene, Kcne2, which is decreased
in expression in both models, is most characterized for its
role in heart disease but has been previously demonstrat-
ed to be reduced in the retina in a rat model of type I
diabetes [6]. Gldc and H2Ab1 are both increased in only
the STZ model. Gldc catalyzes glycine into glyoxylate.
H2Ab1 is a histone family gene and an abundant protein in
chromatin. Alterations in histone expression could poten-
tially have roles in epigenetic control of gene expression
and present another example of an attractive focus for
further experimentation.
Relationship between the animal models
This report is, to our knowledge, the first direct comparison
of retinal gene expression changes in the STZ and
Ins2
Akita mouse models of type I diabetes and demon-
strates that while there are commonly regulated genes,
there are also substantial differences in the gene expres-
sion response at 3 months of hyperglycemia. Previous
studies have compared the gene and protein expression
changes with diabetes (e.g., [3]) and found significant
differences between rodent strains, most likely attribut-
able to genetic background. To eliminate any contribut-
ing variables from the genetic background in the
comparison of the two mouse models, both experimental
groups in this study shared the C57BL/6J genetic
background, making the single nucleotide change in the
Ins2 gene the only genetic difference between the two
models. Both models had similar levels of glycemic
insult (blood glucose and HbA1c at sacrifice) and have
been demonstrated to show increased vascular perme-
ability and neuronal death/dysfunction [9–11, 14, 15, 27].
A potential cause of the differences between the two
models could arise from the initiating event, for example,
non-beta cell toxicity with STZ, or from varied progres-
sion of the diabetes process, as the percent beta cell loss
and concomitant decrease in circulating insulin has not
been quantified in either model at comparable time points.
Further characterization of functional and molecular
events in the context of specific intermediate durations of
diabetes will be required to interpret the differences
observed between the STZ-induced and the Ins2
Akita
retinal transcriptomes, as well as the differences between
the two mouse models and the STZ-induced rat model.
These findings add to the knowledge of the retinal
molecular alterations in response to diabetes in two
widely used mouse models. The ultimate goal of this
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Fig. 3 Quantitative polymerase chain reaction confirmation of
common microarray changes between the two models. *p<0.05,
**p<0.01, t test, n=6–9/group, C control, D diabetic
j ocul biol dis inform (2009) 2:202–213 211research is to improve clinical care of diabetic patients,
and these models should share important commonalities
w i t ht h eh u m a nc o n d i t i o n .W h i l et h em o u s em o d e l s
examined here share key features with the human disease
state (e.g., vascular leakage, apoptosis, and neuronal
dysfunction), our knowledge of the time course of
molecular changes in the human retina with diabetes
remains limited due to the difficulties in obtaining
samples. Comprehensive studies from human (or non-
human primate) tissue are critically needed to provide a
comparator for data sets from other animal models. This
would allow for careful comparison of various animal
models to the human condition and rationale choices of
models for both drug development and basic science
studies.
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